- Home
- BODI vs LUNG Comparison
BODI vs LUNG Comparison
Compare BODI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- LUNG
- Stock Information
- Founded
- BODI 1998
- LUNG 1995
- Country
- BODI United States
- LUNG United States
- Employees
- BODI N/A
- LUNG N/A
- Industry
- BODI Industrial Machinery/Components
- LUNG Industrial Specialties
- Sector
- BODI Industrials
- LUNG Health Care
- Exchange
- BODI Nasdaq
- LUNG Nasdaq
- Market Cap
- BODI 57.9M
- LUNG 63.6M
- IPO Year
- BODI N/A
- LUNG 2020
- Fundamental
- Price
- BODI $8.89
- LUNG $1.67
- Analyst Decision
- BODI Buy
- LUNG Buy
- Analyst Count
- BODI 2
- LUNG 7
- Target Price
- BODI $8.00
- LUNG $6.81
- AVG Volume (30 Days)
- BODI 613.8K
- LUNG 1.2M
- Earning Date
- BODI 11-10-2025
- LUNG 11-12-2025
- Dividend Yield
- BODI N/A
- LUNG N/A
- EPS Growth
- BODI N/A
- LUNG N/A
- EPS
- BODI N/A
- LUNG N/A
- Revenue
- BODI $282,565,000.00
- LUNG $91,664,000.00
- Revenue This Year
- BODI N/A
- LUNG $10.41
- Revenue Next Year
- BODI N/A
- LUNG $10.98
- P/E Ratio
- BODI N/A
- LUNG N/A
- Revenue Growth
- BODI N/A
- LUNG 15.59
- 52 Week Low
- BODI $3.38
- LUNG $1.31
- 52 Week High
- BODI $10.99
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- BODI 68.10
- LUNG 51.13
- Support Level
- BODI $7.44
- LUNG $1.31
- Resistance Level
- BODI $10.99
- LUNG $1.74
- Average True Range (ATR)
- BODI 1.06
- LUNG 0.15
- MACD
- BODI 0.32
- LUNG -0.00
- Stochastic Oscillator
- BODI 64.82
- LUNG 45.63
About BODI The Beachbody Company Inc.
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.